[A24-02] Pembrolizumab (gastric cancer, HER2-negative) – Benefit assessment according to §35a Social Code Book V
Last updated 02.04.2024
Project no.:
A24-02
Commission:
Commission awarded on 02.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1); in combination with fluoropyrimidine and platinum-containing chemotherapy for first-line treatment
Indication of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-02_en